A Two-Part First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Subcutaneous Doses of GUB014295 in Lean to Overweight or Obese But Otherwise Healthy Men and Women
Latest Information Update: 16 May 2025
At a glance
- Drugs Long acting amylin analog (Primary)
- Indications Obesity
- Focus Adverse reactions; First in man
- Acronyms GUBamy
- Sponsors Gubra
Most Recent Events
- 16 May 2025 New Source identified and integrated (ClinicalTrials.gov: US National Institutes of Health;NCT06144684)
- 05 Mar 2025 New trial record